LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,093
تعداد مقالات10,025
تعداد مشاهده مقاله27,282,943
تعداد دریافت فایل اصل مقاله7,501,845
Ghayumi, Seiyed Mohammad Ali, Fallahi, Mohammad Javad, Moarref, Ali Reza. (1392). Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease. سامانه مدیریت نشریات علمی, 38(June Supplement 2013), 163-168.
Seiyed Mohammad Ali Ghayumi; Mohammad Javad Fallahi; Ali Reza Moarref. "Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease". سامانه مدیریت نشریات علمی, 38, June Supplement 2013, 1392, 163-168.
Ghayumi, Seiyed Mohammad Ali, Fallahi, Mohammad Javad, Moarref, Ali Reza. (1392). 'Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease', سامانه مدیریت نشریات علمی, 38(June Supplement 2013), pp. 163-168.
Ghayumi, Seiyed Mohammad Ali, Fallahi, Mohammad Javad, Moarref, Ali Reza. Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease. سامانه مدیریت نشریات علمی, 1392; 38(June Supplement 2013): 163-168.

Effects of Pentoxifylline on Oxygenation and Exercise Tolerance in Patients with Severe Chronic Obstructive Pulmonary Disease

Iranian Journal of Medical Sciences
مقاله 4، دوره 38، June Supplement 2013، فروردین 2013، صفحه 163-168    اصل مقاله (803.81 K)
نوع مقاله: Original Article(s)
نویسندگان
Seiyed Mohammad Ali Ghayumi* 1؛ Mohammad Javad Fallahi2؛ Ali Reza Moarref3
1Department of Internal Medicine, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Internal Medicine, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran;
3Cardiovascular Research Center, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
چکیده
Background: It was hypothesized that the use of Pentoxifylline would increase arterial O2 saturation and increase exercise tolerance in patients with Chronic Obstructive Pulmonary Disease (COPD).
Methods: We tested this hypothesis in 23 patients with COPD and pulmonary hypertension. Patients were randomized to receive Pentoxifylline or placebo, each for a 12-week period, in a prospective, double-blind study to assess the effects of Pentoxifylline on oxygen saturation and exercise tolerance via pulse oximetry and the 6-Minute Walk Test (6MWT).
Results: At the end of the 12 weeks, the six-minute walk distance rose from 351.9±65 meters to 393±67 meters in the Pentoxifylline group (10 patients) and increased from 328±79 meters to 353±66 meters in the placebo group (10 patients) (P=0.142). Resting oxygen saturation by pulse oximetry changed from 87±4% to 85±14% in the Pentoxifylline group and from 88±3% to 88±2% in the placebo group (P=0.676). There were no significant changes in dyspnea severity index and heart rate before and after the 6MWT.
Conclusion: Pentoxifylline does not seem to improve exercise capacity and dyspnea in patients with severe and very severe COPD.
Trial Registration Number: IRCT201202018889N1
کلیدواژه‌ها
COPD؛ Oxygenation؛ Pentoxifylline
آمار
تعداد مشاهده مقاله: 1,879
تعداد دریافت فایل اصل مقاله: 652


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب